Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKesson
Merck

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR APREMILAST


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Apremilast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00456092 ↗ Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis Completed Amgen Phase 2 2007-03-05 This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
NCT00456092 ↗ Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis Completed Celgene Corporation Phase 2 2007-03-05 This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
NCT00521339 ↗ Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Amgen Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00521339 ↗ Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00604682 ↗ Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis Completed Amgen Phase 2 2005-01-01 Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Apremilast

Condition Name

Condition Name for Apremilast
Intervention Trials
Psoriasis 23
Psoriatic Arthritis 15
Plaque Psoriasis 9
Atopic Dermatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Apremilast
Intervention Trials
Psoriasis 42
Arthritis 19
Arthritis, Psoriatic 18
Dermatitis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Apremilast

Trials by Country

Trials by Country for Apremilast
Location Trials
United States 538
Canada 128
Japan 51
Australia 38
Germany 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Apremilast
Location Trials
California 35
Florida 33
Texas 30
New York 29
Georgia 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Apremilast

Clinical Trial Phase

Clinical Trial Phase for Apremilast
Clinical Trial Phase Trials
Phase 4 23
Phase 3 29
Phase 2 38
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Apremilast
Clinical Trial Phase Trials
Completed 61
Recruiting 15
Withdrawn 7
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Apremilast

Sponsor Name

Sponsor Name for Apremilast
Sponsor Trials
Celgene Corporation 50
Amgen 49
Celgene 22
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Apremilast
Sponsor Trials
Industry 129
Other 91
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Harvard Business School
AstraZeneca
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.